Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Health Outcomes in Rheumatoid Arthritis in Greece

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: non interventional

First Posted Date: 2009-10-26

Last Posted Date: 2014-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 210

Registration Number: NCT01001182

Locations: 🇬🇷
Pfizer Investigational Site, Thessaloniki, Greece

A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: reference [dextromethorphan]
Drug: test [PF-00299804 + dextromethorphan]

First Posted Date: 2009-10-22

Last Posted Date: 2010-01-07

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT00999817

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis

Completed

Conditions: Arthritis, Psoriatic
Psoriasis

Interventions: Other: questionnaire

First Posted Date: 2009-10-21

Last Posted Date: 2012-11-29

Lead Sponsor: Pfizer

Target Recruit Count: 458

Registration Number: NCT00998829

Locations: 🇦🇺
Pfizer Investigational Site, Parkville, Victoria, Australia

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Phase 2

Terminated

Conditions: Cystitis, Interstitial

Interventions: Biological: Tanezumab
Other: Placebo

First Posted Date: 2009-10-21

Last Posted Date: 2021-08-03

Lead Sponsor: Pfizer

Target Recruit Count: 205

Registration Number: NCT00999518

Locations: 🇺🇸
Alpha Clinical Research, Brighton, Massachusetts, United States
🇺🇸
TriCities Medical Research, Bristol, Tennessee, United States
🇨🇦
Urology Associates / Urologic Medical Research, Kitchener, Ontario, Canada

and more 166 locations

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Bapineuzumab 0.5 mg/kg

First Posted Date: 2009-10-20

Last Posted Date: 2016-01-01

Lead Sponsor: Pfizer

Target Recruit Count: 494

Registration Number: NCT00998764

Locations: 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇬🇧
Llandough Hospital, Universtity Hospital of Wales, Cardiff, Wales, United Kingdom

and more 177 locations

Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Bacterial Infections

Interventions: Drug: Azithromycin SR

First Posted Date: 2009-10-20

Last Posted Date: 2012-05-01

Lead Sponsor: Pfizer

Target Recruit Count: 502

Registration Number: NCT00998309

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Bapineuzumab 0.5 mg/kg
Drug: Bapineuzumab 1.0 m/kg

First Posted Date: 2009-10-16

Last Posted Date: 2014-01-01

Lead Sponsor: Pfizer

Target Recruit Count: 198

Registration Number: NCT00996918

Locations: 🇬🇧
Pfizer Investigational Site, Swindon, United Kingdom

A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Sitaxentan sodium

First Posted Date: 2009-10-15

Last Posted Date: 2012-02-07

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT00995566

Locations: 🇩🇪
Pfizer Investigational Site, Hannover, Germany

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Phase 2

Terminated

Conditions: Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions: Drug: Tanezumab 5 mg
Drug: Tanezumab 10 mg
Drug: Tanezumab 2.5 mg

First Posted Date: 2009-10-14

Last Posted Date: 2021-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 679

Registration Number: NCT00994890

Locations: 🇺🇸
OrthoArkansas, PA, Little Rock, Arkansas, United States
🇺🇸
Radiology Consultants, Little Rock, Arkansas, United States
🇺🇸
Montana Medical Research, Inc, Missoula, Montana, United States

and more 90 locations

To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects

Completed

Conditions: Pain

Interventions: Drug: PF-04531083

First Posted Date: 2009-10-09

Last Posted Date: 2009-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT00992316

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy